Spread of Artemisinin Resistance in Plasmodium falciparum Malaria
Apple (Israel) · Mahidol Oxford Tropical Medicine Research Unit · +26 more institutions
Abstract
Artemisinin resistance in Plasmodium falciparum has emerged in Southeast Asia and now poses a threat to the control and elimination of malaria. Mapping the geographic extent of resistance is essential for planning containment and elimination strategies.
Between May 2011 and April 2013, we enrolled 1241 adults and children with acute, uncomplicated falciparum malaria in an open-label trial at 15 sites in 10 countries (7 in Asia and 3 in Africa). Patients received artesunate, administered orally at a daily dose of either 2 mg per kilogram of body weight per day or 4 mg per kilogram, for 3 days, followed by a standard 3-day course of artemisinin-based combination therapy. Parasite counts in peripheral-blood samples were measured every 6 hours, and the parasite clearance half-lives were determined.
Citation impact
- FWCI
- 231.25
- Percentile
- 100%
- References
- 32
Authors
83- EAElizabeth A. AshleyCorresponding
Apple (Israel), Mahidol Oxford Tropical Medicine Research Unit, Hospital for Tropical Diseases
- MDMehul Dhorda
University of Maryland, Baltimore, Howard Hughes Medical Institute, Hospital for Tropical Diseases
- RMRick M. Fairhurst
National Institutes of Health, National Institute of Allergy and Infectious Diseases
- CAChanaki Amaratunga
National Institutes of Health, National Institute of Allergy and Infectious Diseases
- PLParath Lim
National Institutes of Health, Cambodia National Malaria Center, National Institute of Allergy and Infectious Diseases
Topics & keywords
- Artemisinin
- Malaria
- Medicine
- Artesunate
- Plasmodium falciparum
- Primaquine
- Internal medicine
- Immunology